Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Praachi Tiwari

4 papers in the library · 35 citations · publishing 2023-2026

Papers

Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI.

Neuron November 20, 2024 Praachi Tiwari, Pasha A. Davoudian, Darshana Kapri et al. 26 citations

The serotonergic psychedelic DOI reduces anxiety-like behavior by activating 5-HT2A receptors on fast-spiking parvalbumin (PV)-positive interneurons in the CA1/subiculum region of the ventral hippocampus. Experiments combining anatomical, pharmacological, and genetic methods showed that these receptors are necessary for the anxiolytic effect. In vivo recordings revealed that DOI increases the firing rate of PV-positive interneurons, most of which express 5-HT2A receptors. Restoring 5-HT2A receptors specifically in PV-positive cells in a loss-of-function background reinstated DOI's anxiety-relieving effects, identifying these interneurons as a cellular trigger for psychedelic-induced relief of anxiety-like behavior.

Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics

Psychedelic Medicine June 1, 2023 Praachi Tiwari, Andrea P Berghella, Ceyda Sayalı et al. 9 citations

Classic psychedelics may treat mood and substance use disorders by reversing learned helplessness, a well-studied phenomenon across mammals. The neural circuits underlying resilience to learned helplessness, including the dorsal raphe nucleus, overlap with those activated by psychedelics. Preclinical data show psychedelics improve performance in rodent behavioral despair tasks, supporting this hypothesis. The learned helplessness paradigm offers a robust model for investigating psychedelic mechanisms across behavioral, neurobiological, and clinical levels, potentially explaining transdiagnostic therapeutic effects.

Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations

medRxiv Preprint Server April 28, 2026 Sandeep M. Nayak, Nathan D. Sepeda, Matthew Nielsen Dick et al. preprint

Psilocybin is being studied as a treatment for psychiatric and neurologic conditions, but there is limited comprehensive data on its cardiovascular safety. Current clinical trials typically exclude people with blood pressure of 140/90 mmHg or higher, a cutoff set conservatively without strong empirical evidence.

Acute DOI treatment evokes dose and species-dependent locomotor effects on the elevated plus maze.

Progress in neuro-psychopharmacology & biological psychiatry December 20, 2025 Praachi Tiwari, Vidita A Vaidya

The serotonergic psychedelic DOI alters locomotor activity in rats and mice in a dose-dependent manner, and these changes correlate with anxiety-like behavior in the elevated plus maze. Species- and strain-specific differences emerge: Sprague-Dawley rats and 129S6/SvEv mice show reduced movement at 1 mg/kg DOI, while C57BL/6J mice show increased movement at the same dose. The locomotor modulation, like the anxiety-related effects, depends on the serotonin 2A receptor, as DOI-evoked changes are absent in 5-HT2A receptor knockout mice. These findings underscore the need to account for psychedelics' effects on spontaneous and context-dependent locomotion when interpreting mood-related behaviors in novelty-based approach-avoidance tasks.